Tuberculosis: From an incurable scourge to a curable disease - Journey over a millennium

Indian Journal of Medical Research

Volumn 137, Issue 3, 2013, Pages 455-493

  Sharma, Surendra K ^a   Mohan, Alladi ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b SRI VENKATESWARA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Clinical manifestations; Diagnosis; Epidemiology; Extensively drug resistant tuberculosis; Human immunodeficiency virus co infection; Multidrug resistant tuberculosis; Treatment; Tuberculosis

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ADALIMUMAB; AMINOSALICYLIC ACID; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; BEDAQUILINE; CARDIOVASCULAR AGENT; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CYTOCHROME P450 3A4; DELAMANID; ETANERCEPT; ETHAMBUTOL; GALLIUM CITRATE GA 67; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; ISONIAZID; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID PLUS RIFAMPICIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PSYCHOTROPIC AGENT; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; SULFONYLUREA; TECHNETIUM 99M; THEOPHYLLINE; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE LUNG INJURY; DIABETES MELLITUS; DRUG SENSITIVITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; EXTRAPULMONARY TUBERCULOSIS; FEVER; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMAGING; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LATENT TUBERCULOSIS; LIVER TOXICITY; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; REVIEW; RISK FACTOR; SERODIAGNOSIS; SMOKING; SUDDEN DEATH; TUBERCULOSIS; TUBERCULOSIS CONTROL; VIRUS HEPATITIS;

ANTITUBERCULAR AGENTS; COINFECTION; HIV INFECTIONS; HUMANS; INDIA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84876421672     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (267)

1. Mohan A, Sharma SK. History. In: Sharma SK, Mohan A, editors. Tuberculosis. 2nd ed. New Delhi: Jaypee Brothers Medical Publishers; 2009. p. 7-15.
2. Rubin SA. Tuberculosis. Captain of all these men of death. Radiol Clin North Am 1995; 33: 619-39.
3. Rosenblatt MB. Pulmonary tuberculosis: evolution of modern therapy. Bull NY Acad Med 1973; 49: 163-96.
4. Dubos R, Dubos J. The white plague. Tuberculosis, man and society. Boston: Little, Brown and Company; 1952.
5. Waksman SA. The conquest of tuberculosis. Berkeley and Los Angeles: University of California Press; 1964.
6. Keers RY. Pulmonary tuberculosis-A journey down the centuries. London: Bailliere-Tindall; 1978.
7. Sakula A. Robert Koch: centenary of the discovery of the tubercle bacillus, 1882. Thorax 1982; 37: 246-51.
8. World Health Organization. TB. A global emergency. WHO Report on the TB epidemic. WHO/TB/94.177. Geneva: World Health Organization; 1994.
9. Sharma SK, Mohan A. Multidrug-resistant tuberculosis. Indian J Med Res 2004; 120: 354-76.
10. Sharma SK, Mohan A. Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control. Chest 2006; 130: 261-72.
11. Central TB Division. Revised National Tuberculosis Control Programme. Guidelines on Programmatic Management of Drug Resistant TB (PMDT) in India. New Delhi: Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare; 2012.
12. [No authors listed]. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 2006; 81: 430-2.
13. Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007; 12: E070517.1.
14. Migliori GB, Loddenkemper R, Blasi F, Raviglione MC. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is science enough to tackle the epidemic? Eur Respir J 2007; 29: 423-7.
15. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, et al. Emergence of new forms of totally drugresistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009; 136: 420-5.
16. Velayati AA, Farnia P, Masjedi MR, Ibrahim TA, Tabarsi P, Haroun RZ, et al. Totally drug-resistant tuberculosis strains: evidence of adaptation at the cellular level. Eur Respir J 2009; 34: 1202-3.
17. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012; 54: 579-81.
18. Mudur G. Indian health ministry challenges report of totally drug resistant tuberculosis. BMJ 2012; 344: e702.
19. Hill AR, Premkumar S, Brustein S, Vaidya K, Powell S, Li PW, et al. Disseminated tuberculosis in the acquired immunodeficiency syndrome era. Am Rev Respir Dis 1991; 144: 1164-70.
20. Sharma SK, Mohan A, Gupta R, Kumar A, Gupta AK, Singhal VK, et al. Clinical presentation of tuberculosis in patients with AIDS: an Indian experience. Indian J Chest Dis Allied Sci 1997; 39: 213-20.
21. Wang JY, Hsueh PR, Wang SK, Jan IS, Lee LN, Liaw YS, et al. Disseminated tuberculosis: a 10-year experience in a medical center. Medicine (Baltimore) 2007; 86: 39-46.
22. Sharma SK, Mohan A. Miliary tuberculosis. In: Agarwal AK, editor. Clinical medicine update-2006. New Delhi: Indian Academy of Clinical Medicine; 2006. p. 353-60.
23. Sharma SK, Mohan A, Sharma A, Mitra DK. Miliary tuberculosis: new insights into an old disease. Lancet Infect Dis 2005; 5: 415-30.
24. Sahn SA, Neff TA. Miliary tuberculosis. Am J Med 1974; 56: 494-505.
25. Sharma SK, Mohan A. Disseminated and miliary tuberculosis. In: Sharma SK, Mohan A, editors. Tuberculosis. 2nd ed. New Delhi: Jaypee Brothers Medical Publishers; 2009. p. 494-518.
26. Baker SK, Glassroth J. Miliary tuberculosis. In: Rom WN, Garay SM, editors. Tuberculosis. Philadelphia: Lippincott Williams and Wilkins; 2004.p.427-44.
27. Sharma SK, Mohan A. Miliary tuberculosis. In: Schlossberg D, editor. Tuberculosis and non-tuberculous mycobacterial diseases. 6th ed. Washington: ASM Press; 2011. p. 415-35.
28. Sharma SK, Mohan A, Sharma A. Challenges in the diagnosis & treatment of miliary tuberculosis. Indian J Med Res 2012; 135: 703-30.
29. World Health Organization. Treatment of tuberculosis. Guidelines. 4th ed. WHO/HTM/ TB/2009.420. Geneva: World Health Organization; 2010.
30. Central TB Division, Government of India. TB India 2012. Revised National TB Control Programme. Annual Status Report. New Delhi: Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare; 2012. Available from: http://tbcindia.nic.in/pdfs/TB%20 India%202012-%20Annual%20Report.pdf, accessed on February 28, 2013.
31. Frieden TR, Munsiff SS. The DOTS strategy for controlling the global tuberculosis epidemic. Clin Chest Med 2005; 26: 197-205, v.
32. Banerjee R, Allen J, Westenhouse J, Oh P, Elms W, Desmond E, et al. Extensively drug-resistant tuberculosis in california, 1993-2006. Clin Infect Dis 2008; 47: 450-7.
33. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, et al. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 113-9.
34. Migliori GB, Centis R, D'Ambrosio L, Spanevello A, Borroni E, Cirillo DM, et al. Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease? Clin Infect Dis 2012; 54: 1379-80.
35. Zumla A, Abubakar I, Raviglione M, Hoelscher M, Ditiu L, McHugh TD, et al. Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis 2012; 205 (Suppl 2): S228-40.
36. "Totally Drug-Resistant TB": a WHO consultation on the diagnostic definition and treatment options 21-22 March 2012 WHO/HQ Geneva, Switzerland. Available from: http://www.who.int/tb/challenges/xdr/Report_Meeting_ totallydrugresistantTB_032012.pdf, accessed on February 28, 2013.
37. World Health Organization. Global tuberculosis control: WHO report 2012. WHO/HTM/ TB/2012.6. Geneva: World Health Organization; 2012. Available from: http://apps.who.int/iris/ bitstream/10665/75938/1/9789241564502_eng.pdf, accessed on February 28, 2013.
38. Chadha VK, Kumar P, Jagannatha PS, Vaidyanathan PS, Unnikrishnan KP. Average annual risk of tuberculous infection in India. Int J Tuberc Lung Dis 2005; 9: 116-8.
39. Chadha VK, Sarin R, Narang P, John KR, Chopra KK, Jitendra R, et al. Trends in the annual risk of tuberculous infection in India. Int J Tuberc Lung Dis 2013; 17: 312-9.
40. Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012; 90: 111-119D.
41. The Stop TB Department, World Health Organization. Available data on anti-TB drug resistance. Available from: http://www.who.int/tb/challenges/mdr/drs_maps.pdf, accessed on February 28, 2013.
42. Ramachandran R, Nalini S, Chandrasekar V, Dave PV, Sanghvi AS, Wares F, et al. Surveillance of drug-resistant tuberculosis in the state of Gujarat, India. Int J Tuberc Lung Dis 2009; 13: 1154-60.
43. Paramasivan CN. Antituberculosis drug resistance surveillance. In: Sharma SK, Mohan A, editors. Tuberculosis. 2nd ed. New Delhi: Jaypee Brothers Medical Publishers; 2009. p. 714-33.
44. Sharma SK, Kumar S, Saha PK, George N, Arora SK, Gupta D, et al. Prevalence of multidrug-resistant tuberculosis among category II pulmonary tuberculosis patients. Indian J Med Res 2011; 133: 312-5.
45. Sharma SK, Kaushik G, Jha B, George N, Arora SK, Gupta D, et al. Prevalence of multidrug-resistant tuberculosis among newly diagnosed cases of sputum-positive pulmonary tuberculosis. Indian J Med Res 2011; 133: 308-11.
46. Thomas A, Ramachandran R, Rehaman F, Jaggarajamma K, Santha T, Selvakumar N, et al. Management of multi drug resistance tuberculosis in the field: Tuberculosis Research Centre experience. Indian J Tuberc 2007; 54: 117-24.
47. Sharma SK, George N, Kadhiravan T, Saha PK, Mishra HK, Hanif M. Prevalence of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: a retrospective hospital-based study. Indian J Med Res 2009; 130: 392-5.
48. Rajasekaran S, Chandrasekar C, Mahilmaran A, Kanakaraj K, Karthikeyan DS, Suriakumar J. HIV coinfection among multidrug resistant and extensively drug resistant tuberculosis patients-a trend. J Indian Med Assoc 2009; 107: 281-2, 284-6.
49. Paramasivan CN, Rehman F, Wares F, Sundar Mohan N, Sundar S, Devi S, et al. First-and second-line drug resistance patterns among previously treated tuberculosis patients in India. Int J Tuberc Lung Dis 2010; 14: 243-6.
50. Thomas A, Joseph P, Nair D, Rao DV, Rekha VV, Selvakumar N, et al. Extensively drug-resistant tuberculosis: experience at the Tuberculosis Research Centre, Chennai, India. Int J Tuberc Lung Dis 2011; 15: 1323-5.
51. Myneedu VP, Visalakshi P, Verma AK, Behera D, Bhalla M. Prevalence of XDR TB cases-a retrospective study from a tertiary care TB hospital. Indian J Tuberc 2011; 58: 54-9.
52. Joseph P, Desai VB, Mohan NS, Fredrick JS, Ramachandran R, Raman B, et al. Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India. Indian J Med Res 2011; 133: 529-34.
53. Balaji V, Daley P, Anand AA, Sudarsanam T, Michael JS, Sahni RD, et al. Risk factors for MDR and XDR-TB in a tertiary referral hospital in India. PLoS One 2010; 5: e9527.
54. Jain S, Rodrigues C, Mehta A, Udwadia ZF. High prevalence of XDR-TB from a tertiary care hospital in India. Am J Respir Crit Care Med 2007; 175: A510.
55. Datta BS, Hassan G, Kadri SM, Qureshi W, Kamili MA, Singh H, et al. Multidrug-resistant and extensively drug resistant tuberculosis in Kashmir, India. J Infect Dev Ctries 2009; 4: 19-23.
56. Murray M, Oxlade O, Lin HH. Modeling social, environmental and biological determinants of tuberculosis. Int J Tuberc Lung Dis 2011; 15 (Suppl 2): S64-70.
57. Lawn SD, Zumla AI. Tuberculosis. Lancet 2011; 378: 57-72.
58. Möller M, de Wit E, Hoal EG. Past, present and future directions in human genetic susceptibility to tuberculosis. FEMS Immunol Med Microbiol 2010; 58: 3-26.
59. Najmi N, Kaur G, Sharma SK, Mehra NK. Human Toll-like receptor 4 polymorphisms TLR4 Asp299Gly and Thr399Ile influence susceptibility and severity of pulmonary tuberculosis in the Asian Indian population. Tissue Antigens 2010; 76: 102-9.
60. Sharma S, Rathored J, Ghosh B, Sharma SK. Genetic polymorphisms in TNF genes and tuberculosis in North Indians. BMC Infect Dis 2010; 10: 165.
61. Rathored J, Sharma SK, Singh B, Banavaliker JN, Sreenivas V, Srivastava AK, et al. Risk and outcome of multidrug-resistant tuberculosis: vitamin D receptor polymorphisms and serum 25(OH)D. Int J Tuberc Lung Dis 2012; 16: 1522-8.
62. Sharma SK, Mohan A, Kadhiravan T. HIV-TB co-infection: epidemiology, diagnosis & management. Indian J Med Res 2005; 121: 550-67.
63. Padmapriyadarsini C, Narendran G, Swaminathan S. Diagnosis & treatment of tuberculosis in HIV co-infected patients. Indian J Med Res 2011; 134: 850-65.
64. Pawlowski A, Jansson M, Sköld M, Rottenberg ME, Källenius G. Tuberculosis and HIV co-infection. PLoS Pathog 2012; 8: e1002464.
65. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995; 151: 129-35.
66. Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, Jacobs WR Jr, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction fragment length polymorphisms. N Engl J Med 1992; 326: 231-5.
67. Modjarrad K, Vermund SH. Effect of treating co-infections on HIV-1 viral load: a systematic review. Lancet Infect Dis 2010; 10: 455-63.
68. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358: 1687-93.
69. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E, et al. Exogenous reinfection with multidrugresistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993; 328: 1137-44.
70. Korenromp EL, Scano F, Williams BG, Dye C, Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis 2003; 37: 101-12.
71. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-21.
72. Narain JP, Raviglione MC, Kochi A. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tuber Lung Dis 1992; 73: 311-21.
73. Toossi Z. Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. J Infect Dis 2003; 188: 1146-55.
74. Centers for Disease Control (CDC). Transmission of multidrug-resistant tuberculosis among immunocompromised persons in a correctional system-New York, 1991. MMWR Morb Mortal Wkly Rep 1992; 41: 507-9.
75. Centers for Disease Control and Prevention (CDC). Outbreak of multidrug-resistant tuberculosis at a hospital-New York City, 1991. MMWR Morb Mortal Wkly Rep 1993; 42: 427, 433-4.
76. Pearson ML, Jereb JA, Frieden TR, Crawford JT, Davis BJ, Dooley SW, et al. Nosocomial transmission of multidrugresistant Mycobacterium tuberculosis. A risk to patients and health care workers. Ann Intern Med 1992; 117: 191-6.
77. Beck-Sague C, Dooley SW, Hutton MD, Otten J, Breeden A, Crawford JT, et al. Hospital outbreak of multidrugresistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients. JAMA 1992; 268: 1280-6.
78. Fischl MA, Daikos GL, Uttamchandani RB, Poblete RB, Moreno JN, Reyes RR, et al. Clinical presentation andoutcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. Ann Intern Med 1992; 117: 184-90.
79. Swaminathan S, Paramasivan CN, Ponnuraja C, Iliayas S, Rajasekaran S, Narayanan PR. Anti-tuberculosis drug resistance in patients with HIV and tuberculosis in South India. Int J Tuberc Lung Dis 2005; 9: 896-900.
80. Pereira M, Tripathy S, Inamdar V, Ramesh K, Bhavsar M, Date A, et al. Drug resistance pattern of Mycobacterium tuberculosis in seropositive and seronegative HIV-TB patients in Pune, India. Indian J Med Res 2005; 121: 235-9.
81. Wells CD, Cegielski P, Nelson LJ, Laserson KF, Holtz TH, Finlay A, et al. HIV infection and multidrug resistant tuberculosis: the perfect storm. J Infect Dis 2007; 196 (Suppl 1): S86-S107.
82. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008; 5: e152.
83. Harries AD, Billo N, Kapur A. Links between diabetes mellitus and tuberculosis: should we integrate screening and care? Trans R Soc Trop Med Hyg 2009; 103: 1-2.
84. Stevenson CR, Forouhi NG, Roglic G, Williams BG, Lauer JA, Dye C, et al. Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health 2007; 7: 234.
85. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010; 36: 1185-206.
86. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A; BSR BR Control Centre Consortium, Symmons DP; BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69: 522-8.
87. Pai M, Mohan A, Dheda K, Leung CC, Yew WW, Christopher DJ, et al. Lethal interaction: the colliding epidemics of tobacco and tuberculosis. Expert Rev Anti Infect Ther 2007; 5: 385-91.
88. Ferrara G, Murray M, Winthrop K, Centis R, Sotgiu G, Migliori GB, et al. Risk factors associated with pulmonary tuberculosis: smoking, diabetes and anti-TNF alpha drugs. Curr Opin Pulm Med 2012; 18: 233-40.
89. Gajalakshmi V, Peto R, Kanaka TS, Jha P. Smoking and mortality from tuberculosis and other diseases in India: retrospective study of 43000 adult male deaths and 35000 controls. Lancet 2003; 362: 507-15.
90. Lin H-H, Ezzati M, Murray M. Tobacco smoke, indoor air pollution and tuberculosis: a systematic review and metaanalysis. PLoS Med 2007; 4: e20.
91. Slama K, Chiang CY, Enarson DA, Hassmiller K, Fanning A, Gupta P, et al. Tobacco and tuberculosis: a qualitative systematic review and meta-analysis. Int J Tuberc Lung Dis 2007; 11: 1049-61.
92. Sharma SK, Mohanan S, Sharma A. Relevance of latent TB infection in areas of high TB prevalence. Chest 2012;142:761-73.
93. Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One 2011; 6: e17601.
94. Sharma SK, Mohan A. Extrapulmonary tuberculosis. Indian J Med Res 2004; 120: 316-53.
95. Marais BJ. Childhood tuberculosis: epidemiology and natural history of disease. Indian J Pediatr 2011; 78: 321-7.
96. Sharma SK, Kadhiravan T, Banga A. A clinical prediction rule to identify patients with tuberculosis at high risk for HIV coinfection. Indian J Med Res 2009; 130: 51-7.
97. Sharma SK, Mohan A, Pande JN, Prasad KL, Gupta AK, Khilnani GC. Clinical profile, laboratory characteristics and outcome in miliary tuberculosis. QJM 1995; 88: 29-37.
98. Proudfoot AT, Akhtar AJ, Douglas AC, Horne NW. Miliary tuberculosis in adults. Br Med J 1969; 2: 273-6.
99. Yu YL, Chow WH, Humphries MJ, Wong RW, Gabriel M. Cryptic miliary tuberculosis. QJM 1986; 59: 421-8.
100. Deng W, Yu M, Ma H, Hu LA, Chen G, Wang Y, et al. Predictors and outcome of patients with acute respiratory distress syndrome caused by miliary tuberculosis: a retrospective study in Chongqing, China. BMC Infect Dis 2012; 12: 121.
101. Lee K, Kim JH, Lee JH, Lee WY, Park MS, Kim JY, et al. Acute respiratory distress syndrome caused by miliary tuberculosis: a multicentre survey in South Korea. Int J Tuberc Lung Dis 2011; 15: 1099-103.
102. Sharma SK, Mohan A, Banga A, Saha PK, Guntupalli KK. Predictors of development and outcome in patients with acute respiratory distress syndrome due to tuberculosis. Int J Tuberc Lung Dis 2006; 10: 429-35.
103. Mohan A, Sharma SK, Pande JN. Acute respiratory distress syndrome (ARDS) in miliary tuberculosis: a twelve year experience. Indian J Chest Dis Allied Sci 1996; 38: 157-62.
104. Hayakawa K, Ramasamy B, Chandrasekar PH. Fever of unknown origin: an evidence-based Review. Am J Med Sci 2012; 344: 307-16.
105. Bandyopadhyay D, Bandyopadhyay R, Paul R, Roy D. Etiological study of fever of unknown origin in patients admitted to medicine ward of a teaching hospital of eastern India. J Glob Infect Dis 2011; 3: 329-33.
106. Grossman C, Kushinka J, Brath LK. A 41-year-old woman with AIDS, mediastinal lymphadenopathy, and fever of unknown origin. Am J Med Sci 2008; 336: 349-52.
107. Sharma SK, Smith-Rohrberg D, Tahir M, Mohan A, Seith A. Radiological manifestations of splenic tuberculosis: a 23-patient case series from India. Indian J Med Res 2007; 125: 669-78.
108. Kingma BJ, van den Berg W, Schuurmans MM, Molenaar AH. A patient with back pain and fever. Eur Respir J 1992; 5: 1292-5.
109. Ibrarullah M, Mohan A, Sarkari A, Srinivas M, Mishra A, Sundar TS. Abdominal tuberculosis: diagnosis by laparoscopy and colonoscopy. Trop Gastroenterol 2002; 23: 150-3.
110. Arch-Ferrer JE, Velázquez-Fernández D, Sierra-Madero J, López-Karpovitch X, Angeles-Angeles A, Gamino R, et al. Laparoscopic approach to fever of unknown origin. Surg Endosc 2003; 17: 494-7.
111. Liu A, Hu Y, Coates A. Sudden cardiac death and tuberculosis-How much do we know? Tuberculosis (Edinb) 2012; 92: 307-13.
112. Biedrzycki OJ, Baithun SI. TB-related sudden death (TBRSD) due to myocarditis complicating miliary TB: a case report and review of the literature. Am J Forensic Med Pathol 2006; 27: 335-6.
113. Breton G, Leclerc S, Longuet P, Leport C, Vildé JL, Laissy JP. Myocardial localisation of tuberculosis: the diagnostic value of cardiac MRI. Presse Med 2005; 34: 293-6.
114. Bansal M, Mehrotra R, Kasliwal RR. Loss of left ventricular torsion as the predominant mechanism of left ventricular systolic dysfunction in a patient with tubercular cardiomyopathy. Echocardiography 2012; 29: E221-5.
115. Baussano I, Nunn P, Williams B, Pivetta E, Bugiani M, Scano F. Tuberculosis among health care workers. Emerg Infect Dis 2011; 17: 488-94.
116. Jarand J, Shean K, O'Donnell M, Loveday M, Kvasnovsky C, Van der Walt M, et al. Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South Africa. Trop Med Int Health 2010; 15: 1179-84.
117. Welbel SF, French AL, Bush P, DeGuzman D, Weinstein RA. Protecting health care workers from tuberculosis: a 10-year experience. Am J Infect Control 2009; 37: 668-73.
118. [No authors listed]. Screening for tuberculosis and tuberculosis infection in high risk populations. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recomm Rep 1995; 44: 19-34.
119. Pinto LM, Grenier J, Schumacher SG, Denkinger CM, Steingart KR, Pai M. Immunodiagnosis of tuberculosis: state of the art. Med Princ Pract 2012; 21: 4-13.
120. Denkinger CM, Dheda K, Pai M. Guidelines on interferongamma release assays for tuberculosis infection: concordance, discordance or confusion? Clin Microbiol Infect 2011; 17: 806-14.
121. Metcalfe JZ, Everett CK, Steingart KR, Cattamanchi A, Huang L, Hopewell PC, et al. Interferon-γ release assays for active pulmonary tuberculosis diagnosis in adults in low-and middle-income countries: systematic review and metaanalysis. J Infect Dis 2011; 204 (Suppl 4): S1120-9.
122. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, et al. Predictive value of interferon-g release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 45-55.
123. National Collaborating Centre for Chronic Conditions and the Centre for Clinical Practice at NICE. Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control. NICE clinical guideline 117. London, England: Royal College of Physicians of London; 2011. Available from: http://www.nice.org.uk/nicemedia/ live/13422/53642/53642.pdf, accessed on February 28, 2013.
124. European Centre for Disease Prevention and Control. Use of interferon-gamma release assays in support of TB diagnosis. Stockholm: European Centre for Disease Prevention and Control; 2011. Available from: http://ecdc.europa.eu/en/ publications/publications/1103_gui_igra.pdf, accessed on February 28, 2013.
125. World Health Organization. Use of tuberculosis interferongamma release assays (IGRAs) in Low-and Middle-Income Countries: Policy Statement. WHO/HTM/TB/ 2011.18. Geneva: World Health Organization; 2011. Available from: http://whqlibdoc.who.int/publications/2011/9789241502672_ eng.pdf, accessed on February 28, 2013.
126. Dheda K, Ruhwald M, Theron G, Peter J, Yam WC. Pointof-care diagnosis of tuberculosis: past, present and future. Respirology 2013; 18: 217-32.
127. Palomino JC. Current developments and future perspectives for TB diagnostics. Future Microbiol 2012; 7: 59-71.
128. Maiga M, Abaza A, Bishai WR. Current tuberculosis diagnostic tools & role of urease breath test. Indian J Med Res 2012; 135: 731-6.
129. Rodrigues C, Shenai S, Sadani M, Sukhadia N, Jani M, Ajbani K, et al. Evaluation of the Bactec MGIT 960 TB system for recovery and identification of Mycobacterium tuberculosis complex in a high through put tertiary care centre. Indian J Med Microbiol 2009; 27: 217-21.
130. Shen GH, Chen CH, Hung CH, Wu KM, Lin CF, Sun YW, et al. Combining the Capilia TB assay with smear morphology for the identification of Mycobacterium tuberculosis complex. Int J Tuberc Lung Dis 2009; 13: 371-6.
131. Tortoli E, Marcelli F. Use of the INNO LiPA Rif. TB for detection of Mycobacterium tuberculosis DNA directly in clinical specimens and for simultaneous determination of rifampin susceptibility. Eur J Clin Microbiol Infect Dis 2007; 26: 51-5.
132. Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010; 48: 1683-9.
133. Dorman SE. New diagnostic tests for tuberculosis: bench, bedside, and beyond. Clin Infect Dis 2010; 50 Suppl 3: S173-7.
134. Parsons LM, Somoskövi A, Gutierrez C, Lee E, Paramasivan CN, Abimiku A, et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev 2011r; 24: 314-50.
135. Shikama Mde L, Silva RR, Martins MC, Giampaglia CM, Oliveira RS, Silva RF, et al. Rapid detection of resistant tuberculosis by nitrate reductase assay performed in three settings in Brazil. J Antimicrob Chemother 2009; 64: 794-6.
136. Martin A, Portaels F, Palomino JC. Colorimetric redoxindicator methods for the rapid detection of multidrug resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 59: 175-83.
137. Lawn SD, Nicol MP. Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol. 2011; 6: 1067-82.
138. Theron G, Pinto L, Peter J, Mishra HK, Mishra HK, van ZylSmit R, et al. The use of an automated quantitative polymerasechain reaction (Xpert MTB/RIF) to predict the sputum smear status of tuberculosis patients. Clin Infect Dis 2012; 54: 384-8.
139. van Zyl-Smit RN, Binder A, Meldau R, Mishra H, Semple PL, Theron G, et al. Comparison of quantitative techniques including Xpert MTB/RIF to evaluate mycobacterial burden. PLoS One 2011; 6: e28815.
140. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a metaanalysis. Eur Respir J 2008; 32: 1165-74.
141. Martin A, Panaiotov S, Portaels F, Hoffner S, Palomino JC, Angeby K. The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2008; 62: 56-64.
142. Ling DI, Flores LL, Riley LW, Pai M. Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. PLoS One 2008; 3: e1536.
143. Neonakis IK, Spandidos DA, Petinaki E. Use of loop-mediated isothermal amplification of DNA for the rapid detection of Mycobacterium tuberculosis in clinical specimens. Eur J Clin Microbiol Infect Dis 2011; 30: 937-42.
144. Boehme CC, Nabeta P, Henostroza G, Raqib R, Rahim Z, Gerhardt M, et al. Operational feasibility of using loopmediated isothermal amplification for diagnosis of pulmonary tuberculosis in microscopy centers of developing countries. J Clin Microbiol 2007; 45: 1936-40.
145. Phillips M, Basa-Dalay V, Bothamley G, Cataneo RN, Lam PK, Natividad MP, et al. Breath biomarkers of active pulmonary tuberculosis. Tuberculosis (Edinb) 2010; 90: 145-51.
146. Phillips M, Basa-Dalay V, Blais J, Bothamley G, Chaturvedi A, Modi KD, et al. Point-of-care breath test for biomarkers of active pulmonary tuberculosis. Tuberculosis (Edinb) 2012; 92: 314-20.
147. World Health Organization. Commercial serodiagnostic tests for diagnosis of tuberculosis: policy statement. WHO/HTM/ TB/2011.5 Geneva: World Health Organization; 2011.
148. Kumar A. Letter of Deputy Director General, Cenral TB Division, Ministry of Health and Family Welfare, Government of India. Available from: http://www.tbcindia.nic.in/pdfs/ Letter_Serodiagnosis.pdf, accessed on February 28, 2013.
149. Seibert AF, Haynes J Jr, Middleton R, Bass JB Jr. Tuberculous pleural effusion. Twenty-year experience. Chest 1991; 99: 883-6.
150. Escudero Bueno C, Garcia Clemente M, Cuesta Castro B, Molinos Martin L, Rodriguez Ramos S, Gonzalez Panizo A, et al. Cytologic and bacteriologic analysis of fluid and pleural biopsy specimens with Cope's needle. Study of 414 patients. Arch Intern Med 1990; 150: 1190-4.
151. Gopi A, Madhavan SM, Sharma SK, Sahn SA. Diagnosis and treatment of tuberculous pleural effusion in 2006. Chest 2007; 131: 880-9.
152. Sharma SK, Suresh V, Mohan A, Kaur P, Saha P, Kumar A, et al. A prospective study of sensitivity and specificity of adenosine deaminase estimation in the diagnosis of tuberculosis pleural effusion. Indian J Chest Dis Allied Sci 2001; 43: 149-55.
153. Sharma SK, Banga A. Pleural fluid interferon-gamma and adenosine deaminase levels in tuberculosis pleural effusion: a cost-effectiveness analysis. J Clin Lab Anal 2005; 19: 40-6.
154. Marshall JB. Tuberculosis of the gastrointestinal tract and peritoneum. Am J Gastroenterol 1993; 88: 989-99.
155. Guirat A, Koubaa M, Mzali R, Abid B, Ellouz S, Affes N, et al. Peritoneal tuberculosis. Clin Res Hepatol Gastroenterol 2011; 35: 60-9.
156. Sharma SK, Tahir M, Mohan A, Smith-Rohrberg D, Mishra HK, Pandey RM. Diagnostic accuracy of ascitic fluid IFNgamma and adenosine deaminase assays in the diagnosis of tuberculous ascites. J Interferon Cytokine Res 2006; 26: 484-8.
157. Fowler NO. Tuberculous pericarditis. JAMA 1991; 266: 99-103.
158. Reuter H, Burgess L, van Vuuren W, Doubell A. Diagnosing tuberculous pericarditis. QJM 2006; 99: 827-39.
159. Galimi R. Extrapulmonary tuberculosis: tuberculous meningitis new developments. Eur Rev Med Pharmacol Sci 2011; 15: 365-86.
160. Cherian A, Thomas SV. Central nervous system tuberculosis. Afr Health Sci 2011; 11: 116-27.
161. Murthy JM. Tuberculous meningitis: the challenges. Neurol India 2010; 58: 716-22.
162. Tuon FF, Higashino HR, Lopes MI, Litvoc MN, Atomiya AN, Antonangelo L, et al. Adenosine deaminase and tuberculous meningitis-a systematic review with meta-analysis. Scand J Infect Dis 2010; 42: 198-207.
163. Xu HB, Jiang RH, Li L, Sha W, Xiao HP. Diagnostic value of adenosine deaminase in cerebrospinal fluid for tuberculous meningitis: a meta-analysis. Int J Tuberc Lung Dis 2010; 14: 1382-7.
164. World Health Organization. Stop TB Partnership and WHO. The global plan to stop TB, 20112015: transforming the fight towards elimination of tuberculosis. Geneva: World Health Organization; 2010.
165. World Health Organization. Expanding and accelerating access to diagnostics for patients at risk of multidrugresistant tuberculosis. Available from: http://www.who.int/tb/ publications/factsheet_expand_tb.pdf, accessed on February 28, 2013.
166. McAdams HP, Erasmus J, Winter JA. Radiologic manifestations of pulmonary tuberculosis. Radiol Clin North Am 1995; 33: 655-78.
167. Jeong YJ, Lee KS. Pulmonary tuberculosis: up-to-date imaging and management. AJR Am J Roentgenol 2008; 191: 834-44.
168. Hara T, Kosaka N, Suzuki T, Kudo K, Niino H. Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. Chest 2003; 124: 893-901.
169. Iyengar KP, Vinjamuri S. Role of 99mTc Sulesomab in the diagnosis of prosthetic joint infections. Nucl Med Commun 2005; 26: 489-96.
170. Singh B, Prasad V, Bhattacharya A, Singh AK, Bhatnagar A, Mittal BR, et al. Diagnosis of mandibular osteomyelitis in probable coexisting tumor recurrence: role of Tc-99m ciprofloxacin imaging. Clin Nucl Med 2008; 33: 525-7.
171. Zhang H, Jiang NY, Zhu L. Experimental studies on imaging of infected site with (99m)Tc-labeled ciprofloxacin in mice. Chin Med J (Engl) 2009; 122: 1907-9.
172. Sharma R, Tewari KN, Bhatnagar A, Mondal A, Mishra AK, Singh AK, et al. Tc-99m ciprofloxacin scans for detection of tubercular bone infection. Clin Nucl Med 2007; 32: 367-70.
173. Bhardwaj V, Agrawal M, Suri T, Sural S, Kashyap R, Dhal A. Evaluation of adequacy of short-course chemotherapy for extraspinal osteoarticular tuberculosis using 99mTc ciprofloxacin scan. Int Orthop 2011; 35: 1869-74.
174. Donald PR, van Helden PD, editors. Antituberculosis chemotherapy. Progress in Respiratory Research, vol.40. Basel: Karger; 2011.
175. Dubos RJ. Bactericidal effect of an extract of a soil bacillus on Gram positive cocci. Proc Soc Exp Biol Med 1939; 40: 311-2.
176. Feldman WH, Hinshaw HC. Effects of streptomycin on experimental tuberculosis in guinea pigs: a preliminary report. Proc Staff Meet Mayo Clin 1944; 19: 593-9.
177. Feldman W, Hinshaw HC, Mann FC. Streptomcin in experimental tuberculosis. Am Rev Tuberc 1945; 52: 269-98.
178. Hinshaw HC, Feldman WH, Pfuetze KH. Treatment of tuberculosis with streptomycin: a summary of observations on one hundred cases. J Am Med Assoc 1946; 132: 778-82.
179. [No authors listed]. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948; 2: 769-82.
180. Lehmann J. Paraaminosalicylic acid in the treatment of tuberculosis. Lancet 1946; 1: 15-6.
181. Treatment of pulmonary tuberculosis with streptomycin and para-amino-salicylic acid; a Medical Research Council investigation. Br Med J 1950; 2: 1073-85.
182. Anonymous. New drugs for tuberculosis. N Engl J Med 1952; 246: 797-9.
183. [No authors listed]. Isoniazid in the treatment of pulmonary tuberculosis; Second report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee. Br Med J 1953; 1: 521-36.
184. Medical Research Council Investigation. Isoniazid in combination with streptomycin or with PAS in the treatment of pulmonary tuberculosis. Br Med J 1953; 2: 1005-14.
185. Long term chemotherapy in the treatment of chronic pulmonary tuberculosis with cavitation: a report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee: Tubercle 1962; 43: 201-67.
186. Wilkerson RG, Sheperd RG, Thomas DP, Baughn C. Stereospecificity in a new type of antituberculosis agent. J Am Chem Soc 1961; 83: 2212-3.
187. Fox W. Ambulatory chemotherapy in a developing country: clinical and epidemiological studies. Adv Tuberc Res 1963; 12: 28-149.
188. Fox W. Methods of chemotherapy in developing countries. Bull Int Union Tuberc 1966; 337: 249-60.
189. Sensi P. History of the development of rifampin. Rev Infect Dis 1983; 5 (Suppl 3): S402-6.
190. [No authors listed]. Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association. Lancet 1976; ii: 1102-4.
191. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003; 7: 6-21.
192. Yeager RL, Munroe WG, Dessau FI. Pyrazinamide (Aldinamide) in the treatment of pulmonary tuberculosis. Am Rev Tuberc 1952; 65: 523-46.
193. [No authors listed]. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972; 1: 1079-85.
194. [No authors listed]. A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society. Br J Dis Chest 1984; 78: 330-6.
195. Chauhan LS. RNTCP: past, present and future of TB control programme in India. J Commun Dis 2006; 38: 191-203.
196. Granich R, Chauhan LS. The Revised National Tuberculosis Control Programme (RNTCP). In: Sharma SK, Mohan A, editors. Tuberculosis. 2nd ed. New Delhi: Jaypee Brothers Medical Publishers; 2009. p. 894-917.
197. Sachdeva KS, Kumar A, Dewan P, Kumar A, Satyanarayana S. New vision for Revised National Tuberculosis Control Programme (RNTCP): Universal access-"Reaching the unreached". Indian J Med Res 2012; 135: 690-4.
198. Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 2009; 6: e1000146.
199. Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010; 50: 1288-99.
200. Swaminathan S, Narendran G, Venkatesan P, Ramachandran R, Sekar L, Iliayas S, et al. Acquired rifampicin resistance in HIV-infected and-uninfected patients with TB treated with a thrice-weekly short-course regimen. Poster presented at Conference on Retroviruses and Opportunistic Infections (CROI), Montreal, 2009. Available from: http://www. retroconference.org/ 2009/Abstracts/35234.htm, accessed on December 29, 2012.
201. Tuberculosis Control India. Available from: http://tbcindia. nic.in, accessed on February 28, 2013.
202. Sharma SK, Solanki R, Mohan A, Jain NK, Chauhan LS; Pleural Effusion Study Group. Outcomes of Category III DOTS treatment in immunocompetent patients with tuberculosis pleural effusion. Int J Tuberc Lung Dis 2012; 16: 1505-9.
203. Jindal SK, Aggarwal AN, Gupta D, Ahmed Z, Gupta KB, Janmeja AK, et al. Tuberculous lymphadenopathy-a multicentre operational study of 6-month, thrice weekly, directly observed therapy. Int J Tuberc Lung Dis 2013; 17: 234-9.
204. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 revision. Geneva: World Health Organization; 2010.
205. Pozniak AL, Coyne KM, Miller RF, Lipman MC, Freedman AR, Ormerod LP, et al; BHIVA Guidelines Subcommittee. British HIV Association guidelines for the treatment of TB/ HIV coinfection 2011. HIV Med 2011; 12: 517-24.
206. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Geneva: World Health Organization; 2011.
207. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42: 819-50.
208. Yew WW. Treatment of tuberculosis. In: Sharma SK, Mohan A, editors. Tuberculosis. 2nd ed. New Delhi: Jaypee Brothers Medical Publishers; 2009. p. 751-75.
209. Sharma SK, Mohan A. Antituberculosis treatment induced hepatotoxicity: from bench to bed-side. In: Gupta SB, editor. Medicine update. Mumbai: Association of Physicians of India; 2005. p. 479-84.
210. Sharma SK. Antituberculosis drugs and hepatotoxicity. Infect Genet Evol 2004; 4: 167-70.
211. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of anti tuberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-52.
212. Singla R, Sharma SK, Mohan A, Makharia G, Sreenivas V, Jha B, et al. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res 2010; 132: 81-6.
213. Sharma SK, Singla R, Sreenivas V, Kumar S, Jha B, Rathored J, Singh S. Acute viral hepatitis as a confounding factor in patients with antituberculosis treatment induced hepatotoxicity. Indian J Med Res 2009;130:200-1.
214. Sarda P, Sharma SK, Mohan A, Makharia G, Jayaswal A, Pandey RM, et al. Role of acute viral hepatitis as a confounding factor in antituberculosis treatment induced hepatotoxicity. Indian J Med Res 2009; 129: 64-7.
215. Sharma SK, Singla R, Sarda P, Mohan A, Makharia G, Jayaswal A, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010; 50: 833-9.
216. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al; American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-62.
217. [No authors listed]. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations. Thorax 1998; 53: 536-48.
218. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, et al; International Network for the Study of HIV-associated IRIS. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8: 516-23.
219. Sharma SK, Soneja M. HIV & immune reconstitution inflammatory syndrome (IRIS). Indian J Med Res 2011; 134: 866-77.
220. Sinha S, Sharma SK. Tuberculosis associated immune reconstitution inflammatory syndrome. Indian J Tuberc 2010; 57: 177-9.
221. Tahir M, Sinha S, Sharma SK, Mitsuyasu RT. Immune reconstitution inflammatory syndrome manifesting as disseminated tuberculosis, deep venous thrombosis, encephalopathy and myelopathy. Indian J Chest Dis Allied Sci 2008; 50: 363-4.
222. Tahir M, Sharma SK, Sinha S, Das CJ. Immune reconstitution inflammatory syndrome in a patient with cryptococcal lymphadenitis as the first presentation of acquired immunodeficiency syndrome. J Postgrad Med 2007; 53: 250-2.
223. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC Jr, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19: 399-406.
224. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosisassociated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21: 335-41.
225. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158: 157-61.
226. Kumarasamy N, Chaguturu S, Mayer KH, Solomon S, Yepthomi HT, Balakrishnan P, et al. Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr 2004; 37: 1574-6.
227. Sharma SK, Dhooria S, Barwad P, Kadhiravan T, Ranjan S, Miglani S, et al. A study of TB-associated immune reconstitution inflammatory syndrome using the consensus case-definition. Indian J Med Res 2010; 131: 804-8.
228. Karmakar S, Sharma SK, Vashishtha R, Sharma A, Ranjan S, Gupta D, et al. Clinical characteristics of tuberculosis associated immune reconstitution inflammatory syndrome in North Indian population of HIV/AIDS patients receiving HAART. Clin Dev Immunol 2011; 2011: 239021.
229. World Health Organization, HIV/AIDS Department. WHO Three I's Meeting: Intensified Case Finding (ICF), Isoniazid Preventive Therapy (IPT) and TB Infection Control (IC) for People Living with HIV. Geneva: World Health Organization; 2008. Available from: http://www.who.int/hiv/ pub/meetingreports/WHO_3Is_meeting_report.pdf, accessed on February 28, 2013.
230. World Health Organization. Implementing the WHO Stop TB strategy: A handbook for national tuberculosis controlprogrammes. WHO/HTM/TB/2008.401. Geneva: World Health Organization; 2008.
231. Menzies D, Al Jahdali H, Al Otaibi B. Recent developments in treatment of latent tuberculosis infection. Indian J Med Res 2011; 133: 257-66.
232. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, et al; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365: 2155-66.
233. Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Isoniazid monotherapy versus other monotherapies or combination chemotherapy for preventing active tuberculosis in HIVnegative persons (Protocol). Cochrane Database Syst Rev 2009, (1). Art. No.: CD007545. Available from: http:// onlinelibrary.wiley.com/doi/10.1002/14651858.CD007545/ pdf, Accessed on February 28, 2013.
234. Cain KP, Nelson LJ, Cegielski JP. Global policies and practices for managing persons exposed to multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2010; 14: 269-74.
235. Lienhardt C, Glaziou P, Uplekar M, Lönnroth K, Getahun H, Raviglione M. Global tuberculosis control: lessons learnt and future prospects. Nat Rev Microbiol 2012; 10: 407-16.
236. Wares DF. Global tuberculosis control: the future prospects. In: Sharma SK, Mohan A, editors. Tuberculosis. 2nd ed. New Delhi: Jaypee Brothers Medical Publishers; 2009. p. 874-93.
237. Landmark meeting on post-2015 TB targets held in Geneva. Available from: http://www.stoptb.org/news/stories/2013/ ns13_012.asp, accessed on February 28, 2013.
238. Sharma SK, Mohan A, Chauhan LS, Narain JP, Behera D, Kumar A, et al; for Task Force for Involvement of Medical Colleges in the Revised National Tuberculosis Control Programme, Govt. of India. Contribution of medical colleges to tuberculosis control in India under the Revised National Tuberculosis Control Programme (RNTCP): lessons learnt & challenges ahead. Indian J Med Res 2013; 137: 283-94.
239. World Health Organization. WHO policy on TB infection control in health-care facilities, congregate settings and households. WHO/HTM/TB/2009.419. Geneva: World Health Organization; 2009.
240. Directorate General of Health Services, Ministry of Health & Family Welfare. Guidelines on airborne infection control in healthcare and other settings in the context of tuberculosis and other airborne infections April 2010 (Provisional). New Delhi: Directorate General of Health Services, Ministry of Health & Family Welfare; 2010.
241. Ottenhoff TH, Kaufmann SH. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog 2012; 8: e1002607.
242. Brennan MJ, Thole J. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis (Edinb) 2012;92 (Suppl 1): S6-S13.
243. Trial of BCG vaccines in south India for tuberculosis prevention. Indian J Med Res 1979; 70: 349-63.
244. Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Tuberculosis Research Centre (ICMR), Chennai. Indian J Med Res 1999; 110: 56-69.
245. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271: 698-702.
246. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of costeffectiveness. Lancet 2006; 367: 1173-80.
247. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al; the MVA85A 020 Trial Study Team. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013; 381: 1021-8.
248. Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, Perkins MD, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010; 375: 1920-37.
249. Wallis RS, Wang C, Doherty TM, Onyebujoh P, Vahedi M, Laang H, et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 2010; 10: 68-9.
250. Swindells S. New drugs to treat tuberculosis. F1000 Med Rep 2012; 4: 12.
251. Zumla A, Hafner R, Lienhardt C, Hoelscher M, Nunn A. Advancing the development of tuberculosis therapy. Nat Rev Drug Discov 2012; 11: 171-2.
252. Villemagne B, Crauste C, Flipo M, Baulard AR, Déprez B, Willand N. Tuberculosis: the drug development pipeline at a glance. Eur J Med Chem 2012; 51: 1-16.
253. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. The challenge of new drug discovery for tuberculosis. Nature 2011; 469: 483-90.
254. Kaufmann SH. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect Dis 2011; 11: 633-40.
255. McShane H. Tuberculosis vaccines: beyond bacille CalmetteGuerin. Philos Trans R Soc Lond B Biol Sci 2011; 366: 2782-9.
256. Ottenhoff TH, Kaufmann SH. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog 2012; 8: e1002607.
257. Brennan MJ, Thole J. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis (Edinb) 2012; 92 (Suppl 1): S6-13.
258. Lee H, Yoon TJ, Weissleder R. Ultrasensitive detection of bacteria using core-shell nanoparticles and an NMR-filter system. Angew Chem Int Ed Engl 2009; 48: 5657-60.
259. Qin D, He X, Wang K, Tan W. Using fluorescent nanoparticles and SYBR Green I based two-color flow cytometry to determine Mycobacterium tuberculosis avoiding false positives. Biosens Bioelectron 2008; 24: 626-31.
260. Veigas B, Machado D, Perdigão J, Portugal I, Couto I, Viveiros M, et al. Au-nanoprobes for detection of SNPs associated with antibiotic resistance in Mycobacterium tuberculosis. Nanotechnology 2010; 21: 415101.
261. Working Group on New TB Drugs. Drug pipeline. Available from: http://www.newtbdrugs.org/pipeline.php, accessed on February 28, 2013
262. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-60.
263. Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56: 3271-6.
264. Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald PR, et al. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother 2012; 56: 3027-31.
265. Hartkoorn RC, Sala C, Neres J, Pojer F, Magnet S, Mukherjee R, et al. Towards a new tuberculosis drug: pyridomycin-nature's isoniazid. EMBO Mol Med 2012; 4: 1032-42.
266. Spigelman M, Woosley R, Gheuens J. New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades. Int J Tuberc Lung Dis 2010; 14: 663-4.
267. Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for tuberculosis elimination. Annu Rev Public Health 2013; 34: 271-86.